Details
Stereochemistry | ACHIRAL |
Molecular Formula | C31H32N6O2 |
Molecular Weight | 520.6248 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CCC(CC1)N2C=NC3=C(NC4=CC=C(C=C4)N5CCOCC5)N=C(OC6=CC=CC7=C6C=CC=C7)N=C23
InChI
InChIKey=FYBHCRQFSFYWPY-UHFFFAOYSA-N
InChI=1S/C31H32N6O2/c1-2-9-25(10-3-1)37-21-32-28-29(33-23-13-15-24(16-14-23)36-17-19-38-20-18-36)34-31(35-30(28)37)39-27-12-6-8-22-7-4-5-11-26(22)27/h4-8,11-16,21,25H,1-3,9-10,17-20H2,(H,33,34,35)
Molecular Formula | C31H32N6O2 |
Molecular Weight | 520.6248 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16408088Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15380183 | https://www.ncbi.nlm.nih.gov/pubmed/21979788 | https://www.ncbi.nlm.nih.gov/pubmed/25341035
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16408088
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15380183 | https://www.ncbi.nlm.nih.gov/pubmed/21979788 | https://www.ncbi.nlm.nih.gov/pubmed/25341035
Purmorphamine is agonist of the protein Smoothened, a key part of the hedgehog signaling pathway, which is involved in bone growth and brain development as well as having a number of other functions in the body. Purmorphamine induces osteogenesis in multipotent mesenchymal progenitor cells. It demonstated neuroprotective action in mouse model of brain ischemia and cytoprotective effect in cellular model of amyotrophic lateral sclerosis.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12465946/
Curator's Comment: The first article was co-authored by The Scripps Research Institute and Genomics Institute of the Novartis Research Foundation. The Scripps Research Institute was applicant of the first patent on purmorphamine.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5971 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16408088 |
1.5 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25341035
Focal ischemia was induced by permanent occlusion of the left middle cerebral artery (MCA) under isoflurane anesthesia. Briefly, a skin incision was made between the orbit and the ear. Under an operating microscope, the temporal muscle was divided to locate the distal course of the left MCA through the translucent skull. A small burr-hole craniotomy was performed with a microdrill and the exposed MCA was coagulated using a bipolar pencil. Permanent occlusion was ensured by physical division. Animals were randomly divided into groups and received a single dose of 1, 5 and 15 mg/kg of purmorphamine (PUR) or VEH (PEG-400: ethanol: water (40 : 20 : 40) i.v. or i.p. at 6 h after MCAO. SHAM-operated animals were injected with VEH. CyP (10 mg/kg) was administered 40 min before PUR.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16408088
Smo binding assays were conducted with BODIPY-cyclopamine and Smo-overexpressing cells using CMV promoter-based, SV40 origin-containing expression constructs for Smo-Myc3, the deletion mutant Smo.Delta.CRD (deletion of amino acids 68 to 182), and Smo.Delta.CT (deletion of amino acids 556 to 793). HEK 293T cells were grown on poly-D-lysine-treated glass coverslips in 12-well plates until 70% confluency and then transfected with the appropriate expression construct (0.5 ug/well) using FuGene 6 according the manufacturer’s protocols. Two days after transfection, the HEK 293T cells were incubated with DMEM containing 0.5% bovine calf serum, 5 nM BODIPY-cyclopamine, and varying concentrations of purmorphamine (0, 1.5, or 5 uM) (1 mL/well) for 1 h at 37 °C. The Smo-overexpressing cells were then washed with 1X PBS buffer (1 mL/well), mounted with DAPI-containing medium, and visualized using a Leica DM4500B fluorescence microscope. For binding assays using fixed cells, the Smo-overexpressing HEK 293T cells were fixed with 3% paraformaldehyde in 1X PBS buffer for 10 min at room temperature (1 mL/well), treated with 1X PBS containing 10 mM glycine and 0.2% sodium azide for 5 min (1 mL/well), washed with 1X PBS buffer (1 mL/well), and treated with the compound-containing media described above for 4 h at room temperature.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:59:46 GMT 2023
by
admin
on
Sat Dec 16 10:59:46 GMT 2023
|
Record UNII |
PB12M2F8KY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m9323
Created by
admin on Sat Dec 16 10:59:46 GMT 2023 , Edited by admin on Sat Dec 16 10:59:46 GMT 2023
|
PRIMARY | Merck Index | ||
|
PB12M2F8KY
Created by
admin on Sat Dec 16 10:59:46 GMT 2023 , Edited by admin on Sat Dec 16 10:59:46 GMT 2023
|
PRIMARY | |||
|
Purmorphamine
Created by
admin on Sat Dec 16 10:59:46 GMT 2023 , Edited by admin on Sat Dec 16 10:59:46 GMT 2023
|
PRIMARY | |||
|
DTXSID20415293
Created by
admin on Sat Dec 16 10:59:46 GMT 2023 , Edited by admin on Sat Dec 16 10:59:46 GMT 2023
|
PRIMARY | |||
|
5284329
Created by
admin on Sat Dec 16 10:59:46 GMT 2023 , Edited by admin on Sat Dec 16 10:59:46 GMT 2023
|
PRIMARY | |||
|
483367-10-8
Created by
admin on Sat Dec 16 10:59:46 GMT 2023 , Edited by admin on Sat Dec 16 10:59:46 GMT 2023
|
PRIMARY |